Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study.
about
Amphetamine, past and present--a pharmacological and clinical perspectiveFuture pharmacological treatments for substance use disordersADHD in Children Onset of Efficacy of Long-Acting Psychostimulants in Pediatric Attention-Deficit/Hyperactivity DisorderAmphetamines for attention deficit hyperactivity disorder (ADHD) in children and adolescentsLisdexamfetamine Dimesylate: Prodrug Delivery, Amphetamine Exposure and Duration of EfficacyLong-acting stimulants for treatment of attention-deficit/hyperactivity disorder: a focus on extended-release formulations and the prodrug lisdexamfetamine dimesylate to address continuing clinical challengesUsing stimulants to treat ADHD-related emotional labilityAssociations of sleep disturbance with ADHD: implications for treatmentComparative efficacy, acceptability, and tolerability of lisdexamfetamine in child and adolescent ADHD: a meta-analysis of randomized, controlled trials.Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuseAn update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorderTargeting the nicotinic cholinergic system to treat attention-deficit/hyperactivity disorder: rationale and progress to dateUpdate on optimal use of lisdexamfetamine in the treatment of ADHD.Safety of stimulant treatment in attention deficit hyperactivity disorder: Part I.Safety of stimulant treatment in attention deficit hyperactivity disorder: part II.A Cost-Utility Analysis of Lisdexamfetamine Versus Atomoxetine in the Treatment of Children and Adolescents with Attention-Deficit/Hyperactivity Disorder and Inadequate Response to Methylphenidate.Update on the management of attention-deficit/hyperactivity disorder in children and adults: patient considerations and the role of lisdexamfetamine.A systematic review of the safety of lisdexamfetamine dimesylate.Lisdexamfetamine dimesylate (vyvanse), a prodrug stimulant for attention-deficit/hyperactivity disorderNew and extended-action treatments in the management of ADHD: a critical appraisal of lisdexamfetamine in adults and children.Lisdexamfetamine dimesylate: the first prodrug stimulant.Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: novel findings using a simulated adult workplace environment design.Lisdexamfetamine dimesylate: a new therapeutic option for attention-deficit hyperactivity disorder.Neuropsychological profile of executive function in girls with attention-deficit/hyperactivity disorderFocus on Lisdexamfetamine: A Review of its use in Child and Adolescent Psychiatry.Executive function deficits in children with attention-deficit/hyperactivity disorder and improvement with lisdexamfetamine dimesylate in an open-label study.Post hoc analyses of the impact of previous medication on the efficacy of lisdexamfetamine dimesylate in the treatment of attention-deficit/hyperactivity disorder in a randomized, controlled trialTreatment response and remission in a double-blind, randomized, head-to-head study of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit hyperactivity disorder.Efficacy and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: sex and age effects and effect size across the day.Parent preferences regarding stimulant therapies for ADHD: a comparison across six European countriesHealth-related quality of life and functional outcomes from a randomized-withdrawal study of long-term lisdexamfetamine dimesylate treatment in children and adolescents with attention-deficit/hyperactivity disorder.Relative bioavailability of lisdexamfetamine 70-mg capsules in fasted and fed healthy adult volunteers and in solution: a single-dose, crossover pharmacokinetic study.Attention-deficit-hyperactivity disorder: an update.Effects of omeprazole on the pharmacokinetic profiles of lisdexamfetamine dimesylate and extended-release mixed amphetamine salts in adults.Efficacy of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder previously treated with methylphenidate: a post hoc analysisThe occurrence of adverse drug reactions reported for attention deficit hyperactivity disorder (ADHD) medications in the pediatric population: a qualitative review of empirical studiesPilot study of the effects of lisdexamfetamine on cocaine use: A randomized, double-blind, placebo-controlled trialDose response effects of lisdexamfetamine dimesylate treatment in adults with ADHD: an exploratory studyADHD treatments, sleep, and sleep problems: complex associationsOnset of abnormal movements and cardiovascular symptoms after acute change in complex polypharmacy in a child with attention-deficit/hyperactivity disorder and mood symptoms.
P2860
Q22241826-3AB2EAD2-6AB6-43BD-A631-98E61CF3373BQ22242633-0777E784-4623-48D5-B764-5183972EC11CQ22305481-C980BD1F-BEB9-4D2D-813D-2E07E762337EQ24186168-6A07CBC6-B3F0-4591-9765-AA314E0752EBQ26750486-5A2B2844-E93D-4C51-B1CE-6923F2842509Q26822392-2E0EB007-8460-4633-AC3F-33C3F8F5E074Q27002372-636C5F8D-CA22-48B2-92E3-FD0DCCB5F3E3Q27027062-B452F481-1CEA-4FE2-B0D9-CD98C97450C1Q27692676-5183E299-D972-4573-B73B-FBF365B8F705Q28239619-B42FDB00-1F59-4822-A20D-5971603A0902Q28246274-DB48E039-E357-428C-8BCE-213FEA22D01DQ28250463-35D2924F-BDFF-48D3-93C9-3324FD2E29FCQ30418053-A3E0DE66-C94F-452B-AA0A-8C3A0A3A205BQ30449130-637DC0F2-4A56-40F2-AE0D-7DD0DE21F0CCQ30451303-07BE9FFC-E7D4-46B4-804D-7756EEB04021Q30489718-C00D809D-BBCD-450B-8F9D-C8BDED62B801Q33571016-49C328D5-69E2-4A3D-BB9E-3DC6F8EB44AFQ33755396-9040CF4E-47DD-479F-B0ED-7DA9494003C3Q33865315-BD79AAC1-F83D-46AB-9490-A92BF3680DC8Q33881547-01295DE8-0FAF-4D7B-9AA9-9E331339FB56Q33894687-D82DA4B4-76FD-4EAE-B016-018EF661011FQ34011677-F39B39D2-7CD0-4905-AE95-B179A39CDA9EQ34032634-EFB4320D-D6E3-4CD0-B343-EBB309279A18Q34215914-20F45D10-58BD-4B1F-8B9F-AD602F586573Q34232286-1EF32CB0-0509-43BA-AA30-BC9D3B785FD9Q34421050-4D49DC52-8424-4625-8B32-F5308CA4C24EQ34449469-3747D2E7-61D5-430D-9BB8-1105280EDAC6Q34459431-C11B3699-7566-4DBF-8E88-48041CE251ACQ34498667-45A1D3D9-759D-444D-85A1-C3E60C7D0740Q34580454-55528A4F-8526-4BDD-B48D-6303636842ECQ34580471-9682F08A-8CE6-45ED-90EA-407F05B0668CQ34752064-0C370C01-201A-4FA7-BD12-7F4F630727A2Q34983475-2B9B370D-660E-4CA4-8FB3-39DF7D663D27Q35007442-CFE92FF1-F8BA-4F57-AFD0-1B35C20EE67EQ35576553-A689D7DE-0D09-4DBC-ABDF-9E9C6ACD1544Q35666363-F9674598-6387-432F-941B-7F59A73C1785Q35875805-505F7077-4B49-4ABA-8C7B-8C59267335DBQ35970045-79CFC5C3-4AB5-4E8E-8BEC-1A6250DB963FQ36233163-6A1FDAD5-9DA6-48C5-A24D-70D1BA34D214Q36493506-6A49B4CC-DB4D-4CF5-B6FA-6B3451C1E103
P2860
Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Efficacy and tolerability of l ...... ed-dose, parallel-group study.
@en
Efficacy and tolerability of l ...... ed-dose, parallel-group study.
@nl
type
label
Efficacy and tolerability of l ...... ed-dose, parallel-group study.
@en
Efficacy and tolerability of l ...... ed-dose, parallel-group study.
@nl
prefLabel
Efficacy and tolerability of l ...... ed-dose, parallel-group study.
@en
Efficacy and tolerability of l ...... ed-dose, parallel-group study.
@nl
P2093
P1476
Efficacy and tolerability of l ...... ed-dose, parallel-group study.
@en
P2093
James J McGough
Robert L Findling
Suma Krishnan
Yuxin Zhang
P304
P356
10.1016/S0149-2918(07)80083-X
P577
2007-03-01T00:00:00Z